These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

445 related articles for article (PubMed ID: 17011380)

  • 1. Tolterodine for treatment of overactive bladder.
    Kanofsky JA; Nitti VW
    Urol Clin North Am; 2006 Nov; 33(4):447-53, viii. PubMed ID: 17011380
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tolterodine for the treatment of overactive bladder.
    Salvatore S; Serati M; Bolis P
    Expert Opin Pharmacother; 2008 May; 9(7):1249-55. PubMed ID: 18422481
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The cost-effectiveness of solifenacin vs fesoterodine, oxybutynin immediate-release, propiverine, tolterodine extended-release and tolterodine immediate-release in the treatment of patients with overactive bladder in the UK National Health Service.
    Cardozo L; Thorpe A; Warner J; Sidhu M
    BJU Int; 2010 Aug; 106(4):506-14. PubMed ID: 20132203
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score.
    Kaplan SA; Roehrborn CG; Chancellor M; Carlsson M; Bavendam T; Guan Z
    BJU Int; 2008 Nov; 102(9):1133-9. PubMed ID: 18510659
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The cost-effectiveness of solifenacin vs fesoterodine, oxybutynin immediate-release, propiverine, tolterodine extended-release and tolterodine immediate-release in the treatment of patients with overactive bladder in the UK National Health Service.
    Warner JL
    BJU Int; 2010 Aug; 106(4):586. PubMed ID: 20653664
    [No Abstract]   [Full Text] [Related]  

  • 6. Re: safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction.
    Schaefer W
    J Urol; 2006 Nov; 176(5):2311-2; author reply 2312-3. PubMed ID: 17070326
    [No Abstract]   [Full Text] [Related]  

  • 7. [Comparisons of efficacy and safety of tolterodine and oxybutynin in children with idiopathic overactive bladder].
    Deng YJ; Ma G; Guo YF; Ge Z; Lu RG; Wang LX; Zhu HB; Chen CJ
    Zhongguo Dang Dai Er Ke Za Zhi; 2011 Jan; 13(1):26-8. PubMed ID: 21251382
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized trial of percutaneous tibial nerve stimulation versus extended-release tolterodine: results from the overactive bladder innovative therapy trial.
    Peters KM; Macdiarmid SA; Wooldridge LS; Leong FC; Shobeiri SA; Rovner ES; Siegel SW; Tate SB; Jarnagin BK; Rosenblatt PL; Feagins BA
    J Urol; 2009 Sep; 182(3):1055-61. PubMed ID: 19616802
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term safety, tolerability and efficacy of extended-release tolterodine in the treatment of overactive bladder in Japanese patients.
    Takei M; Homma Y;
    Int J Urol; 2005 May; 12(5):456-64. PubMed ID: 15948744
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of solifenacin in patients previously treated with tolterodine extended release 4 mg: results of a 12-week, multicenter, open-label, flexible-dose study.
    Chancellor MB; Zinner N; Whitmore K; Kobashi K; Snyder JA; Siami P; Karram M; Laramée C; Capo' JP; Seifeldin R; Forero-Schwanhaeuser S; Nandy I
    Clin Ther; 2008 Oct; 30(10):1766-81. PubMed ID: 19014833
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patient satisfaction with extended release tolterodine or oxybutynin in overactive bladder.
    Bolge SC; McDonnell DD; Chen A; Wan GJ
    Curr Med Res Opin; 2007 Aug; 23(8):1903-12. PubMed ID: 17610806
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The clinical efficacy of tolterodine extended-release is maintained for 24 h in patients with overactive bladder.
    Dmochowski R; Kreder K; MacDiarmid S; Carlsson M; Guan Z
    BJU Int; 2007 Jul; 100(1):107-10. PubMed ID: 17552957
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tolterodine extended release with or without tamsulosin in men with lower urinary tract symptoms including overactive bladder symptoms: effects of prostate size.
    Roehrborn CG; Kaplan SA; Jones JS; Wang JT; Bavendam T; Guan Z
    Eur Urol; 2009 Feb; 55(2):472-9. PubMed ID: 18583022
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tolterodine extended-release for overactive bladder.
    Chung DE; Te AE
    Expert Opin Pharmacother; 2009 Sep; 10(13):2181-94. PubMed ID: 19663610
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and tolerability of tolterodine extended release in male and female patients with overactive bladder.
    Dmochowski R; Abrams P; Marschall-Kehrel D; Wang JT; Guan Z
    Eur Urol; 2007 Apr; 51(4):1054-64; discussion 1064. PubMed ID: 17097217
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Editorial comment on: Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockers.
    Dmochowski R
    Eur Urol; 2009 Sep; 56(3):542. PubMed ID: 19070419
    [No Abstract]   [Full Text] [Related]  

  • 17. Editorial comment on: Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockers.
    Speakman MJ
    Eur Urol; 2009 Sep; 56(3):542-3. PubMed ID: 19070420
    [No Abstract]   [Full Text] [Related]  

  • 18. Fesoterodine for the treatment of overactive bladder.
    Tzefos M; Dolder C; Olin JL
    Ann Pharmacother; 2009 Dec; 43(12):1992-2000. PubMed ID: 19920160
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Superior efficacy of fesoterodine over tolterodine extended release with rapid onset: a prospective, head-to-head, placebo-controlled trial.
    Kaplan SA; Schneider T; Foote JE; Guan Z; Carlsson M; Gong J
    BJU Int; 2011 May; 107(9):1432-40. PubMed ID: 20860717
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tolterodine extended release is efficacious in continent and incontinent subjects with overactive bladder.
    Rovner ES; Rackley R; Nitti VW; Wang JT; Guan Z;
    Urology; 2008 Sep; 72(3):488-93. PubMed ID: 18639327
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.